Search our Trials
Search Results
Trial Number
Mechanism of Action
Drug Classifications
Target Required
Conditions
Site
20210023
n/a
n/a
CDKN2A null, MTAP null
Solid Tumor
MCD
1403-0011 (Brightline-2)
BI 907828 is a so-called MDM2 inhibitor
n/a
MDM2 Amplified, TP53 Wild-type
Biliary, Bladder, Lung, Pancreatic
MCD
18-26
Adagrasib is a potent, highly selective and orally available small molecule inhibitor of a form of KRAS that harbors an oncogenic substitution mutation (G12C).mutation (G12C).
Smal Molecule Inhibitor
Yes
other solid tumors)
MCD
19-09
CTX-471 is a fully humanized IgG4 agonist antibody for CD-137, also known as 4-1BB, a costimulatory factor for T cells and NK cells.
Monoclonal Antibody, Targeted Therapy
Not Required
Advanced Malignancies, head and neck squamous cell carcinoma (HNSCC), Melanoma, Mesothelioma, Non-Small Cell Lung, small-cell lung
MCD
20-06
SRK-181, an anti-latent TGFβ1 monoclonal antibody, is an agent designed to target the latent TGFβ1 complex, preventing TGFβ1 activation in an isoform-specific manner.
Monoclonal Antibody
no
and Squamous Cell Carcinoma of Head and Neck, Clear Cell Renal Cell Carcinoma, Melanoma, Non-Small Cell Lung, urothelial carcinoma
MCD
20-08
TAK-676 is a synthetic cyclic dinucleotide (CDN) exhibiting highly selective binding and activation of STING pathway.
Immunotherapy, targeted
n/a
Colorectal, head and neck squamous cell carcinoma, Solid Tumor
MCD
20-13
NT-I7 is a human IL-7 fusion protein that promotes T cell development which plays a central role in immune response.
Cytokines, Immunotherapy
Not Required
Colorectal, Non-Small Cell Lung, ovarian cancer, Pancreatic, small-cell lung, Solid Tumors, triple negative Breast
MCD
20-23
THOR-707, the IL-2 variant moiety binds to dimers containing the IL-2 receptor beta and gamma chains (IL2Rbg; IL2Rbetagamma) on immune cells activating these cells and...
recombinant human IL-2 variant
Not required
Solid Tumors
MCD
20-26
 GDC-0077- PI3K inhibitor• Idasanutlin – MDM2 protein antagonist Alectinib – ALK kinase inhibitor trastuzumab Emtansine – HER2 antibody-drug conjugate  Ipatasertib – AKT inhibitor  Atezolizumab –...
Antibody Drug Conjugate, Monoclonal Antibody, Small Molecule, Targeted Therapy
Yes
Solid Tumors
MCD
21-04
AdAPT-001 is an oncolytic adenovirus that expresses a TGF-β (beta) trap fusion protein
Oncolytic virus
N/A
Solid Tumors with Injectable Lesion
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.